JAGX

Jaguar HealthA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$4.30

Analysis reference price unavailable

Analysis 2026-10-21 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$2.80

Analysis reference price unavailable

Analysis 2026-10-21 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$1.10

Analysis reference price unavailable

Analysis 2026-10-21 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-21

AI commentary

The packet's October 20 anchor of $2.63 is about 45% below the prior baseline's October 9 anchor of $4.79, but Series R dividend mechanics make a simple per-share comparison potentially misleading; available evidence does not establish what drove the move. The October 14 company release is constructive but preliminary, not a controlled readout. No reliable analyst revisions, current target coverage, options, short-interest, employee or social measurements were supplied; zero-valued sentiment fields mean unavailable, not neutral. The deterministic prior is positive, but low coverage, loose valuation peers and nearer-term funding obligations support cautious monitoring.

RankAlpha Sentiment Codex - 2026-10-21

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-11-02eventSeries R preferred-share conversionHigh impact

Each outstanding Series R preferred share is scheduled to convert into five common shares on November 2. The October 13 record date and October 16 ex-dividend date make entitlement important when comparing per-share prices; a lower common-share quote alone does not measure a dividend recipient's economic return [#8-K-2026-10-05]. SEC filing; company dividend update.

2026-12-31eventMVID clinical-package readinessHigh impact

Jaguar said it expected the clinical package supporting a pediatric MVID application to be ready by year-end 2026. Completion and regulatory alignment remain to be demonstrated [#SEC-8K-2026-08-19]. SEC-filed results exhibit.

2027-01-01eventJanuary debt and royalty-payment testHigh impact

September amendments deferred a Streeterville note maturity and the start of two royalty-payment streams to January 1, 2027. Each stream then requires at least $750,000 monthly; the deferral does not establish that Jaguar can fund those obligations without further financing [#8-K-2026-10-05]. SEC filing.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-21 • Updated nightlySource: Internal modelMethodology